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Abstract  Chagas  disease  is  among  the  neglected  tropical  diseases  recognized  by  the  World
Health Organization  that  have  received  insufficient  attention  from  governments  and  health
agencies.
Chagas disease  is  endemic  in  21  Latin  America  regions.  Due  to  globalization  and  increased
migration,  it  has  crossed  borders  and  reached  other  regions  including  North  America  and  Europe.
The clinical  presentation  of  the  disease  is  highly  variable,  from  general  symptoms  to  severe
cardiac involvement  that  can  culminate  in  heart  failure.  Chagas  heart  disease  is  multifacto-
rial, and  can  include  dilated  cardiomyopathy,  thromboembolic  phenomena,  and  arrhythmias
that may  lead  to  sudden  death.  Diagnosis  is  by  methods  such  as  enzyme-linked  immunosorbent
assay (ELISA)  and  the  degree  of  cardiac  involvement  should  be  investigated  with  complemen-
tary exams  including  ECG,  chest  radiography  and  electrophysiological  study.  There  have  been
insufficient  studies  on  which  to  base  specific  treatment  for  heart  failure  due  to  Chagas  disease.
Treatment  should  therefore  be  derived  from  guidelines  for  heart  failure  that  are  not  specific
for this  disease.  Heart  transplantation  is  a  viable  option  with  satisfactory  success  rates  that  has
improved survival.
©  2020  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an





Cardiopatia  chagásica  e  insuficiência  cardíaca:  da  epidemiologia  ao  tratamento
Resumo  A  doença  de  Chagas  é  uma  das  reconhecidas  pela  Organização  Mundial  de  SaúdeDoença  de  Chagas; (OMS) entre  um  grupo  de  doenças  que  receberam  atenção  insuficiente  de  governos  e  órgãos  de
démica  em  21  regiões  da  América  Latina.  Devido  à  globalização  e




A doença  de  Chagas  é  en
ao aumento  da  migração,  aMorte  súbita América do  Norte  e  a  Europa.  A  apresentação  clínica  da  doença  pode  ser  muito  variada,  pois  gera
desde sintomas  gerais  até  comprometimento  cardíaco  grave,  capaz  de  culminar  em  insuficiência
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cardíaca.  A  cardiopatia  é  multifatorial  e,  dessa  forma,  pode  expressar-se  em  miocardiopatia
dilatada, fenómenos  tromboembólicos  e  arritmias  que  podem  levar  à  morte  súbita.  O  diagnós-
tico deve  ser  feito  utilizando  métodos  como  o  estudo  imunoenzimático  (ELISA)  e  a  investigação
do grau  de  acometimento  cardíaco  deve  ser  realizada  com  outros  exames  complementares,
como ECG,  radiografia  do  tórax,  estudo  eletrofisiológico,  entre  outros.  Os  estudos  científicos
são insuficientes  para  propor  um  tratamento  específico  para  insuficiência  cardíaca  por  doença  de
Chagas.  Portanto,  o  tratamento  deve  ser  extrapolado  das  diretrizes  para  insuficiência  cardíaca
que não  são  específicas  para  essa  doença.  Atualmente,  sabe-se  que  o  transplante  cardíaco  é
uma opção  viável  que  melhora  a  sobrevida  e  apresenta  taxas  de  sucesso  satisfatória.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é um








































































hagas  disease  was  first  described  by  the  Brazilian  physician
arlos  Chagas  in  1909.1--3 He  identified  the  etiologic  agent,
he  parasite  Trypanosoma  cruzi, as  well  as  elucidating  its  life
ycle.4 It  is  a  neglected  tropical  disease  which  is  transmitted
ia  the  feces  of  a  triatomine-infected  vector  through  a  bite
ound  or  mucous  membrane.1,5 Oral  and  vertical  transmis-
ion,  blood  transfusion  and  organ  transplantation  are  other
ossible  routes  of  dissemination.6
Chagas  disease  used  to  be  endemic,  restricted  to  Latin
merica.  However,  increased  immigration  has  transformed
his  local  problem  into  a  global  public  health  issue.  It  affects
etween  eight  and  12  million  adults  around  the  world,
ncluding  in  Europe,  North  America,  Japan  and  Australia.1,7,8
Chronic  Chagas  cardiomyopathy  occurs  in  20-40%  of
nfected  individuals,  and  is  its  most  important  consequence,
s  it  is  potentially  lethal.  This  condition  has  various  manifes-
ations,  including  arrhythmias,  heart  failure,  stroke,  heart
lock,  thromboembolism  and  sudden  death.9 Megaesopha-
us,  megacolon  and  autonomic  nervous  system  dysfunction
re  common  extracardiac  complications.1
In  this  article,  we  review  the  epidemiology,  pathophys-
ology,  clinical  manifestations,  treatment  and  prognosis
f  Chagas  disease,  focusing  on  its  cardiac  consequences.
 thorough  understanding  of  Chagas  disease  and  its
omplications  is  crucial  to  the  correct  management  of  this
isease.
pidemiology
hagas  disease  is  endemic  in  21  Latin  America  regions.  Tra-
itionally,  the  disease  was  transmitted  through  the  vector,
hich  lives  in  the  mud  walls  of  rural  houses  in  developing
ountries.  However,  patterns  of  migration  and  new  forms
f  dissemination  have  led  to  the  current  geographic  dis-
ribution  of  the  disease.10 Its  prevalence  has  decreased  in
ecent  years  due  to  blood  transfusion  screening  and  vector
ontrol.11
Currently,  the  area  with  the  highest  incidence  of  Cha-
as  disease  is  the  Bolivian  Chaco,  where  the  infection  rate




on-ischemic  cardiomyopathy  in  the  country,  affecting  7%  of
dults.7,12 In  Brazil,  the  distribution  of  the  disease  is  uneven,
n  line  with  the  country’s  continental  proportions.13 Between
008  and  2017,  2086  new  cases  of  acute  Chagas  disease  were
eported  in  Brazil,  95.3%  of  which  were  in  the  north:  the
tate  of  Pará  had  the  highest  number  of  cases  in  that  period
1739),  while  the  Northeast  reported  56  new  patients.  The
reas  with  the  lowest  incidence  were  the  Federal  District
f  Brasilia  and  the  states  of  Piauí,  Espírito  Santo  and  Rio  de
aneiro,  with  only  one  case  each.13
Vector  control  programs  begun  during  the  twentieth  cen-
ury  brought  benefits  to  Latin  America  and  by  the  end
f  the  century  had  succeeded  in  eradicating  vector  trans-
ission  in  Uruguay,  Chile  and  some  regions  of  Brazil.  As
ther  forms  of  disease  spread  are  less  important  in  these
reas,  the  risk  of  transmission  of  Chagas  disease  is  close  to
ero  at  these  sites.14--16 However,  due  to  globalization  and
ncreased  migration,  Chagas  disease  has  crossed  the  borders
f  endemic  regions  and  reached  North  America,  Europe,  Aus-
ralia  and  Japan.17 The  prevalence  of  Chagas  disease  in  Latin
mericans  living  in  Europe  is  around  4.2%.18 In  the  US,  it  is
stimated  that  more  than  100  000  individuals  are  affected
y  the  disease.19
In  a  study  conducted  in  New  York  City,  analysis  of  a  sample
f  patients  from  Latin  America  with  dilated  cardiomyopa-
hy  concluded  that  Chagas  disease  was  the  cause  of  cardiac
nvolvement  in  up  to  13%  of  cases.20 However,  the  disease
s  considered  to  be  underdiagnosed,  with  an  estimated  95%
f  cases  being  undiagnosed.21 Thus,  data  on  the  disease  and
ts  cardiovascular  repercussions  are  imprecise.
tiology and pathophysiology
he  etiologic  agent  of  Chagas  disease  is  T.  cruzi, which
ccurs  in  two  forms  when  it  infects  humans:  trypomastig-
tes  and  amastigotes.  The  agent  circulates  via  blood-sucking
riatomine  vectors  and  presents  a  genetic  variety  that  deter-
ines  its  pathogenicity  and  response  to  therapy.  Currently,.  cruzi  is  divided  into  six  discrete  typing  units  (TcI-TcVI).22
The  most  prevalent  form  of  transmission  of  the  disease  is
y  vector,  mainly  in  endemic  areas.  The  cycle  of  the  etiolog-




















































Chagas  cardiomyopathy  and  heart  failure:  From  epidemiolog
Initially,  a  triatomine  bug  bites  a  human  and  simultaneously
passes  feces  infected  with  the  metacyclic  trypomastigote
form  of  the  parasite,  thus  beginning  the  human  stage.  The
parasites  then  penetrate  the  site  of  the  bite  or  a  mucous
membrane  and  invade  several  cells  near  the  penetration
site,  where  they  transform  into  amastigotes.  The  latter  mul-
tiply  by  binary  division,  transform  into  trypomastigotes  and
burst  out  of  the  host  cell,  entering  the  blood  circulation.  The
parasite  can  thereby  infect  new  cells,  where  it  turns  into  the
amastigote  form,  restarting  the  cycle  or  being  ingested  by
a  new  vector  feeding  on  host  blood.23
If  it  is  ingested  by  the  vector,  the  vector  stage  of  the  cycle
begins.  The  trypomastigote  form  becomes  an  epimastigote
in  the  midgut  of  the  vector  and  begins  to  replicate.  In  the
hindgut,  epimastigotes  differentiate  into  metacyclic  trypo-
mastigotes  that  are  then  eliminated  in  the  feces  of  the
vector,  giving  rise  to  a  new  cycle  of  infection.23
The  Amazon  Basin  region,  which  has  the  best  domes-
tic  vector  control,  has  seen  a  significant  increase  in  oral
transmission  by  foods  contaminated  with  T.  cruzi. In  Brazil
between  2008  and  2017,  69.5%  of  new  cases  of  the  acute
form  of  Chagas  disease  were  attributed  to  oral  transmission
of  the  disease.13 Chile  and  Uruguay  managed  to  halt  vector
transmission  in  the  2000s.2
Other  forms  of  disease  transmission  are  found  in  both
endemic  and  non-endemic  countries.  Blood  dissemination
has  an  estimated  transmission  rate  of  10-25%.24,25 Infection
by  solid  organ  transplantation  from  infected  donors  varies
according  to  what  has  been  transplanted.  The  estimated
rate  for  kidney  transplantation  ranges  from  0-13%  while  the
rate  for  infected  heart  recipients  may  reach  100%.26--28
Vertical  transmission  is  also  reported,  with  an  estimated
rate  of  3.9-5.6%.29 There  are  important  factors  that  influ-
ence  the  transmission  potential  of  this  mechanism.  High
maternal  parasitemia  increases  the  probability  of  transmis-
sion,  depending  on  which  discrete  typing  units  are  involved.
A  study  conducted  in  Brazil  suggested  that  TcII  has  a  lower
transmission  rate  than  TcV.30 Ingestion  of  contaminated  food
and  laboratory  accidents  have  been  reported,  but  are  less
frequent  forms  of  transmission.31,32
The  disease  presents  an  initial  acute  phase  that  begins
1-2  weeks  after  infection  and  lasts  for  up  to  4-8  weeks.33
At  this  stage,  there  is  extensive  parasitism  and  infec-
tion,  particularly  of  certain  tissues  such  as  esophageal,
colon  and  heart  muscle  and  the  central  nervous  system.34,35
The  parasite  infects  these  target  tissues  by  transmigration
through  the  vascular  barrier  with  the  aid  of  bradykinin  and
the  chemokine  CCL2.36 The  process  may  elicit  an  immune
response  mediated  by  activation  of  CD4+  and  CD8+  T  cells
and  B  cells.37 As  a  result,  myocarditis  may  develop  with
mononuclear  and  polymorphonuclear  infiltrates,  interstitial
edema,  vasculitis,  and  myocyte  necrosis.34,35
After  this  stage,  the  chronic  phase  begins,  at  which  point
the  heart  may  become  involved.  The  pathogenesis  of  Chagas
cardiomyopathy  is  the  result  of  a  range  of  aggressive  mech-
anisms  that  culminate  in  cardiac  injury,  the  main  ones  of
which  are  parasite  persistence,  immunological  mechanisms,
autonomic  nervous  system  derangement  and  microcircula-
tory  disturbances.38
Parasite  persistence  appears  to  be  the  most  important
mechanism  in  the  genesis  of  Chagas  cardiomyopathy.  The
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s  inhibition  of  cardiomyocyte  caspase  activity  mediated
y  nuclear  factor  kappa  B  and  the  Bcl-2  protein.39 During
he  chronic  phase,  the  amastigote  coexists  with  the  host
ell,  generating  constant  low-grade  inflammation  leading
o  chronic  myocarditis.  Thus,  parasite  persistence  leads  to
brosis  and  cardiac  remodeling.40,41
During  the  chronic  phase  of  the  disease,  there  is  an
xaggerated  type  1  T  helper  (Th1)  immune  response  with
elease  of  interferon  gamma  and  tumor  necrosis  factor
lpha,  decreased  release  of  interleukin  (IL)-10,  and  sup-
ression  of  Th2  response-related  cytokines  such  as  IL-4.42,43
n  addition,  polymorphisms  in  inflammatory  genes  (BAT1,
embrane  cofactor  protein-1,  lymphotoxin  alpha)  have
een  reported  in  relation  to  the  genesis  of  chronic  Chagas
ardiomyopathy.44,45
Neurogenic  disturbances  are  involved  in  at  least  three
ifferent  aspects  of  the  development  of  the  disease.38 Early
arasympathetic  impairment  is  present  in  patients  with
alignant  arrhythmias  and  sudden  death.46 In  early  stages
f  the  disease,  dyssynergic  areas  are  found  in  both  ventri-
les.  Finally,  it  is  thought  that  autonomic  derangement  may
rigger  microcirculatory  vasospasm.38
Chagas  cardiomyopathy  results  in  changes  in  the
icrovascular  circulation.  There  are  reports  of  chronic
erivascular  inflammation,  capillary  basement  membrane
hickening,  increases  in  prothrombotic  components,  factors
eading  to  aneurysm  formation,  alterations  in  vasoconstric-
ion  and  vasodilation  leading  to  ischemia,  necrosis,  and
eparative  fibrosis.38
Microscopically,  mononuclear  cell  infiltration  is  observed,
omposed  of  varying  numbers  of  lymphocytes,  plasma
ells,  histiocytes,  and  eosinophils.  Granulomas  and  multi-
ucleated  giant  cells  may  also  be  found.  Intracytoplasmic
mastigote  forms  are  seen  less  frequently.47
In  autopsies,  varying  degrees  of  biventricular  dilata-
ion,  hypertrophy  and  fibrosis  of  the  myocardium  and
picardium  are  found.  Other  reported  alterations  include
eft  ventricular  aneurysms  and  mural  thrombi  that  are  not
xclusive  to  Chagas  disease.47 Epicardial  plaques  (known
s  ‘milk  spots’)  may  also  be  observed;  these  are  rarer  in
he  general  population  and  are  more  specific  to  Chagas
ardiomyopathy.47,48
linical presentation
he  clinical  presentation  of  Chagas  disease  is  divided  into
hree  phases:  acute,  indeterminate  and  chronic.  After  an
ncubation  period  of  1-2  weeks,49 the  acute  phase  of  the
isease  begins,  which  lasts  from  six  to  eight  weeks.50
lthough  most  patients  show  no  early  signs,  non-specific
ymptoms  may  occur  in  the  acute  phase,  including  fever,
alaise,  muscle  pain,  hepatosplenomegaly,  anorexia,  vom-
ting  and  diarrhea.  In  a  few  cases,  signs  at  the  infection
ite  may  be  present:  Romaña’s  sign  (painless  prolonged
dema  of  the  eyelid)  and  chagoma  (elsewhere  on  the  skin).50
ewer  than  1%  of  cases  present  with  meningoencephalitis
r  myocarditis  in  the  acute  phase  due  to  the  severe  form
f  the  disease.51 Cardiac  complications  in  the  initial  phase
re  more  frequently  associated  with  oral  transmission  than
ector-borne  infection,  due  to  better  control  of  T.  cruzi
nside  homes.52
























































Table  1  Clinical  staging  of  chronic  heart  failure  according
to findings  of  follow-up  exams.
Stage  Findings
A  Normal  ECG,  no  heart  disease,  symptoms
or  structural  disorder
B1  Asymptomatic  with  ECG  changes  and  no  LV
dysfunction
B2 Asymptomatic  with  LV  dysfunction  but  no
symptoms  of  HF
C LV  dysfunction  and  current  or  previous
symptoms  of  HF
D  Refractory  symptoms  of  HF  at  rest  despite








































Usually,  the  acute  phase  of  the  disease  resolves  spon-
aneously  even  without  therapeutic  intervention  and  the
atient  becomes  chronically  infected.  Thus,  most  patients
evelop  the  indeterminate  form  of  the  disease,  which  is  cha-
acterized  by  absence  of  symptoms  or  signs  of  cardiac  or
igestive  tract  involvement  and  no  alterations  on  the  elec-
rocardiogram  (ECG)  or  chest  X-ray,  but  with  seropositivity
or  T.  cruzi. This  form  of  the  disease  presents  an  excellent
rognosis.53
Decades  after  the  acute  and  indeterminate  phases,  less
han  half  of  patients  develop  the  cardiac  and/or  gastroin-
estinal  involvement  that  characterizes  the  chronic  stage
f  Chagas  disease.  Gastrointestinal  manifestations  occur  in
5-20%  of  patients,  including  dilatation  of  the  gastrointesti-
al  tract,  mainly  the  esophagus  and  colon  (rectum  and
igmoid).54 This  dilatation  is  due  to  loss  of  muscle  tone
s  a  consequence  of  chronic  inflammation  of  the  enteric
lexus  and  degeneration  of  intestinal  neurons.55 The  spec-
rum  of  esophageal  disease  presentation  is  varied,  ranging
rom  mild  asymptomatic  achalasia  to  severe  megaesophagus
ith  regurgitation,  aspiration,  cough,  dysphagia,  odynopha-
ia  and  weight  loss.56 Colon  disease  manifests  as  megacolon
ith  chronic  constipation  leading  to  fecalomas,  volvulus  and
ven  ischemia  of  the  region.57
Chronic  Chagas  cardiomyopathy  is  estimated  to  affect  20-
0%  of  infected  patients.49 Cardiac  symptoms  arise  with  the
rogressive  destruction  of  cardiomyocytes,  accumulation  of
nterstitial  collagen,  and  damage  to  the  cardiac  conduction
ystem.38 Chagas  heart  disease  occurs  in  a  segmental  pattern
nd  may  present  a  wide  range  of  alterations  depending  on
he  cardiac  site  affected.  These  changes  frequently  include
ilated  cardiomyopathy,  thromboembolic  phenomena,  and
rrhythmias  that  may  lead  to  sudden  death.
Early  cardiac  changes  may  include  multiform  premature
entricular  contractions,  right  bundle  branch  block  or  left
nterior  fascicular  block.58,59 Its  highly  arrhythmogenic  and
rogressive  nature  may  lead  to  persistent  changes  in  the
onduction  system,  such  as  severe  bradycardia  due  to  sinus
ode  dysfunction,  atrial  fibrillation,  atrial  flutter,  atrioven-
ricular  (AV)  block,  premature  ventricular  contractions,  and
ustained  and  non-sustained  ventricular  tachycardia.5,49,58,59
t  this  stage  of  the  disease,  the  patient  may  have  preserved
entricular  function.  Pulmonary  and  systemic  thromboem-
olic  phenomena  are  reported,  as  well  as  apical  aneurysm
ormation.60,61
Infected  patients  may  develop  biventricular  dilated  car-
iomyopathy  and  congestive  heart  failure.60 A  Brazilian
tudy  of  infected  blood  donors  showed  a  progression  to  car-
iomyopathy  of  1.85%  per  year.62 At  the  present  time,  this
orm  of  transmission  is  no  longer  found  because  of  screen-
ng  of  blood  donors.  It  has  also  been  observed  that  regions
ith  effective  vector  control  presented  a  lower  prevalence
f  severe  Chagas  cardiomyopathy  because  patients  did  not
resent  an  inflammatory  response  due  to  repeated  contact
ith  the  antigen.63
Cardiovascular  involvement  in  the  chronic  phase  of  Cha-
as  disease  can  be  classified  according  to  the  presence  of
entricular  dysfunction  and  heart  failure  symptoms  accord-
ng  to  Latin  American  guidelines  for  the  diagnosis  and
reatment  of  Chagas’  heart  disease  (Table  1).50
Patients  in  stage  A  have  no  cardiac  alterations  and  are






ECG: electrocardiographic; HF: heart failure; LV: left ventricular.
1,  individuals  are  asymptomatic  but  present  alterations  on
he  ECG  or  on  echocardiography.  Stage  B2  indicates  asymp-
omatic  patients  with  ventricular  dysfunction  but  no  heart
ailure,  while  stage  C  indicates  the  presence  of  ventricu-
ar  dysfunction  and  current  or  previous  symptoms  of  heart
ailure  due  to  Chagas  cardiomyopathy.  In  stage  D  refractory
eart  failure  symptoms  are  present  at  rest  even  with  optimal
herapy.  At  this  stage  patients  need  intensive  interventions.
Heart  failure  syndrome  begins  with  exertion-related  dys-
nea  and  fatigue.  As  the  condition  progresses,  the  symptoms
nd  signs  of  pulmonary  and  systemic  congestion  become
ore  evident.  Subsequently,  paroxysmal  nocturnal  dyspnea,
rthopnea,  jugular  venous  engorgement,  hepatomegaly,
orsening  lower  limb  edema  and  anasarca  appear.  Cardio-
ascular  signs  may  include  displacement  of  the  apex  beat,
uffled  cardiac  sounds,  third  heart  sound,  or  systolic  regur-
itation  murmur  due  to  dilation  of  the  annuli  of  the  AV
alves.  Reduced  systemic  blood  pressure  associated  with
hready  pulse  may  also  be  present.  Crackles  on  pulmonary
uscultation  demonstrate  pulmonary  congestion.
Arrhythmic  manifestations  may  arise  in  conjunction  with
eart  failure  syndrome  or  separately.  Clinical  examination
ay  reveal  irregular  heart  rhythm,  bradycardia  or  tachy-
ardia,  or  splitting  of  the  second  heart  sound.  In  complete
V  block,  cannon  A  waves  in  the  jugular  venous  pulse  may
e  observed  at  the  base  of  the  neck.  The  most  common
ntraventricular  conduction  abnormality  found  in  Chagas
ardiomyopathy  is  right  bundle  branch  block,  which  can
ffect  up  to  28.8%  of  patients.64-66 When  associated  with
nterior  fascicular  block,  the  condition  becomes  more  char-
cteristic  of  the  disease  and  requires  further  investigation.
eft  bundle  branch  block  is  less  frequent  and  when  present
s  indicative  of  worse  prognosis.64-66 The  most  common  atrial
achycardia  is  atrial  fibrillation,  which  affects  up  to  5.4%  of
atients.64 It  is  strongly  associated  with  stroke  risk  and  is
n  important  predictor  of  mortality.66 Monomorphic  or  poly-
orphic  premature  ventricular  complexes  are  commonly
ound  ventricular  tachyarrhythmias,  affecting  up  to  66%
f  patients.67 Tachyarrhythmias  originating  in  the  ventri-
les  are  strongly  associated  with  the  occurrence  of  sudden
eath.  Ventricular  tachyarrhythmias  may  be  related  to  car-
iac  areas  with  perfusion  deficits  and  hypokinesia,  with  the
nferolateral  region  of  the  left  ventricle  being  the  most  com-
on  focus.68--70
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Chagas  cardiomyopathy  and  heart  failure:  From  epidemiolog
Stroke  and  systemic  embolism  are  possible  manifesta-
tions  in  the  chronic  phase  of  Chagas  disease.  The  origin  of
the  thrombi  is  usually  inside  the  cardiac  chambers,  related
to  loss  of  function  and  atrial  arrhythmias.71,72 Atrial  fibrilla-
tion,  left  ventricular  systolic  dysfunction,  apical  aneurysm
and  left  ventricular  thrombus  are  reported  as  risk  factors  for
stroke.71,73 However,  non-embolic  causes  of  stroke  are  also
found,  including  cryptogenic  (25.5%),  small  vessel  disease
(9.5%),  and  large  vessel  atherosclerosis  (8.5%).  Presentation
is  similar  to  those  without  Chagas  disease,  such  as  motor  or
sensory  deficit,  dysarthria,  aphasia  and  visual  changes.74
Some  studies  reveal  cognitive  alterations  and  vascular
dementia  in  endemic  regions,  even  in  patients  without
cardiac  alterations.75 Cerebral  atrophy  has  been  found  in
patients  in  the  chronic  phase  of  the  disease  with  no  rela-
tion  to  brain  infarcts.76,77 However,  studies  have  not  found
the  parasite  in  brain  tissue77 and  atrophy  is  believed  to  be  a
manifestation  of  the  multifactorial  nature  of  the  disease  and
its  systemic  involvement.76 Cardiac  arrhythmias  and  con-
gestive  heart  failure  leading  to  chronic  hypoxemia,  reduced
Purkinje  cell  numbers,  spinocerebellar  tract  and  dorsal  col-
umn  demyelination,  extensive  cell  loss  in  the  substantia
nigra  and  locus  coeruleus,  and  a  basal  ganglia  lacunar  state
are  reported  as  alterations  that  may  lead  to  neurological
manifestations.78
Diagnosis
In  the  acute  phase,  the  most  sensitive  diagnostic  method
is  identification  of  T.  cruzi  genetic  material  by  polymerase
chain  reaction.33 Other  diagnostic  forms  used  include  xen-
odiagnosis,  blood  culture,  direct  visualization  of  the  parasite
in  peripheral  blood,  and  biopsy  of  infected  organs.  At  this
early  stage  of  the  disease,  electrocardiographic  changes
may  already  be  detected,  mainly  in  patients  with  myocardi-
tis.  The  examination  may  reveal  sinus  tachycardia,  low  QRS
voltage,  prolonged  PR  and/or  QT  interval,  ventricular  repo-
larization  abnormalities,  atrial  fibrillation  and  ventricular
arrhythmias.50
The  indeterminate  form  is  characterized  by  serological
or  parasitological  evidence  of  the  infection,  but  absence  of
signs  or  symptoms  or  changes  on  the  ECG  or  chest  X-ray.
There  may  be  slight  changes  in  more  sensitive  exams  such
as  echocardiography,  cardiac  magnetic  resonance  imag-
ing  (MRI),  Holter  monitoring,  myocardial  scintigraphy  or
endomyocardial  biopsy.  However,  studies  do  not  correlate
these  findings  with  the  prognosis  of  the  disease.50
In  the  chronic  phase,  parasitemia  is  low  and  therefore
the  most  effective  diagnostic  methods  involve  identifi-
cation  of  antibodies  against  the  etiologic  agent.  The
main  techniques  used  are  indirect  immunofluorescence,
enzyme-linked  immunosorbent  assay  (ELISA)  and  indirect
hemagglutination.
The  earliest  changes  indicative  of  Chagas  cardiomyopa-
thy  usually  appear  on  the  ECG.  Right  bundle  branch  disorders
and  left  anterior  hemiblock  are  highly  characteristic  findings
of  this  stage  of  cardiac  involvement.  The  other  above-
mentioned  arrhythmias  can  also  be  detected  on  the  ECG.
Polymorphic  ventricular  extrasystoles,  atrial  fibrillation  and
atrial  flutter  are  associated  with  more  advanced  ventricular




atient  with  Chagas  cardiomyopathy.
ithout  ventricular  dysfunction,  but  tend  to  be  related  to
ore  advanced  stages  and  worse  prognosis.  Patients  who
resent  left  ventricular  dysfunction  and/or  syncope  are  indi-
ated  for  Holter  continuous  electrocardiographic  monitoring
o  detect  bradyarrhythmias  or  tachyarrhythmias  that  are  not
bserved  on  a routine  ECG.50
Chest  radiography  may  be  useful  for  assessing  the  dis-
ase  in  more  advanced  stages  (Figure  1).  Cardiomegaly  with
nlargement  of  the  right  and  left  heart  chambers  may  be
bserved.  However,  pulmonary  congestion  is  usually  mild  or
on-existent.50
Echocardiography  is  indicated  for  all  patients  presenting
ith  Chagas  disease,  in  whom  it  can  assess  systolic  and  dias-
olic  synchronicity  and  the  presence  of  intracavitary  thrombi
nd  apical  aneurysms.  In  the  indeterminate  phase,  some
atients  may  present  left  ventricular  segmental  wall  motion
bnormalities  even  if  a  previous  ECG  was  normal.  In  more
dvanced  stages,  the  examination  may  reveal  dilatation  of
he  cardiac  chambers  associated  with  global  hypokinesia.
ilatation  of  valve  annuli  secondary  to  cardiomegaly  leads  to
itral  and/or  tricuspid  regurgitation.  Ventricular  aneurysms
re  also  a  common  finding  in  this  phase  and  are  associated
ith  up  to  67%  of  cases  associated  with  high  thromboem-
olic  risk.50 Echocardiography  is  not  routinely  indicated  for
atients  with  Chagas  cardiomyopathy.  Eligible  patients  are
hose  with  new  electrocardiographic  changes,  worsening
unctional  class  or  a  new  cardiovascular  event.67
Radioisotope  ventriculography  is  an  alternative  to
chocardiography  that  provides  the  most  accurate  assess-
ent  of  ventricular  function  for  patients  with  Chagas
isease.79 This  exam  does  not  suffer  from  geometric  inter-
erence  from  the  heart  when  calculating  left  ventricular
jection  fraction  (LVEF)  and  is  able  to  assess  right  and
eft  ventricular  dysfunction  simultaneously  and  the  presence
f  ventricular  dyssynchrony.80,81
Stress  testing  is  useful  for  the  screening  and  prognosis  of
tress-induced  arrhythmias.  Cardiopulmonary  exercise  test-
ng  and  myocardial  perfusion  scintigraphy  are  viable  options
o  assess  coronary  perfusion;  scintigraphy  shows  segmental
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Figure  2  Cardiac  magnetic  resonance  imaging  showing  congestive  heart  failure/cardiomyopathy  of  probable  inflammatory  etiology
( ed  b












































Chagas myocarditis),  with  significant  dysfunction  and  increas
ricuspid regurgitation,  dilated  left  atrium  and  mitral  insufficie
erfusion  defects  in  about  30%  of  patients  with  anginal  pain
nd  normal  coronary  angiography.50
MRI  is  a  high-quality  and  well-established  test  for  assess-
ng  cardiac  anatomy  and  function  (Figure  2).  It  is  able  to
etermine  cardiac  chamber  volume  and  degree  of  contrac-
ility,  as  well  as  to  diagnose  thrombus  if  present.  The  most
ffective  analysis  of  cardiac  tissue  is  by  infusion  of  gadolin-
um,  which  can  identify  and  quantify  areas  of  the  heart  with
brosis.82,83
Some  patients  develop  malignant  arrhythmias  without
lobal  ventricular  systolic  dysfunction  but  with  myocardial
brosis  that  can  be  detected  by  MRI.84,85
Electrophysiological  study  (EPS)  can  be  used  to  assess
inus  node  function  and  AV  conduction  in  patients  with  signs
nd/or  symptoms  for  which  there  is  no  pathophysiological
xplanation  documented  by  non-invasive  tests.  The  main
ndications  for  EPS  are  syncope,  resuscitated  sudden  death
nd  tachyarrhythmias  which  can  potentially  be  controlled
y  ablative  therapy.50
Cardiac  catheterization  is  indicated  for  patients  with
hagas  cardiomyopathy  who  present  with  angina  symptoms,
lectrocardiographic  alterations  compatible  with  myocar-
ial  ischemia,  and/or  segmental  left  ventricular  wall  motion
bnormalities  on  echocardiography.  The  ECG  may  reveal
athological  Q  waves  and  ST-T  segment  changes.  In  the
ast  majority  of  cases,  the  examination  reveals  no  signif-




iventricular  diameters,  significantly  dilated  right  atrium  and
and  pericardial  effusion.
rocedure  can  measure  pulmonary  vascular  resistance  and  is
hus  indicated  for  patients  eligible  for  heart  transplantation
o  assess  the  feasibility  of  the  procedure.67
reatment
n  the  acute  phase,  antiparasitic  treatment  is  recommended
or  all  patients.  Regardless  of  the  mechanism  of  infection,
enznidazole  and  nifurtimox  are  the  drugs  of  choice  and
an  reduce  the  duration  of  illness  and  its  symptoms.  Para-
itic  cure  after  treatment  is  achieved  in  60-90%  of  patients
ndergoing  treatment.86--88
Antiparasitic  treatment  of  the  indeterminate  and  chronic
orms  remains  controversial.  According  to  the  BENEFIT  trial,
 randomized  study  with  more  than  2800  patients  that
ssessed  the  efficacy  of  benznidazole  in  Chagas  disease,
here  was  no  benefit  in  preventing  progression  of  cardiac
nvolvement  in  patients  with  established  Chagas  cardiomy-
pathy.  Thus,  patients  with  established  heart  disease  should
ot  receive  routine  treatment  with  benznidazole.89 How-
ver,  there  is  consensus  that  trypanocidal  therapy  should
e  provided  to  female  patients  of  reproductive  age  in  order
o  prevent  vertical  transmission  and  in  cases  of  reactivation
y  immunosuppression.87
Although  there  are  no  studies  that  prove  the  effective-
ess  of  pharmacological  treatment  for  Chagas  heart  disease,
he  treatment  of  heart  failure  is  based  on  conventional
y  to  treatment  285
Table  2  Rassi  score  for  mortality  risk  stratification  in  Cha-
gas disease.
Clinical  features  Points
Cardiomegaly  on  chest  X-ray  5
NYHA class  III  or  IV 5
Nonsustained  ventricular  tachycardia  on
Holter  monitoring
3
Segmental  or  global  wall  motion
abnormalities  on  echocardiography
3





































transplantation  is  an  alternative  for  patients  with  Cha-
gas  cardiomyopathy  and  has  satisfactory  success  rates.  TheChagas  cardiomyopathy  and  heart  failure:  From  epidemiolog
treatment  for  dilated  cardiomyopathy  of  other  etiologies.
Therapy  for  systolic  heart  failure  consists  of  a  combina-
tion  of  beta-blockers  and  angiotensin-converting  enzyme
inhibitors  (ACEIs)  or  angiotensin  receptor  blockers  (ARBs).
For  patients  in  New  York  Heart  Association  (NYHA)  functional
class  II  to  IV  and  with  LVEF  ≤35%,  an  aldosterone  receptor
antagonist  may  be  added.  For  patients  with  persistent  symp-
toms  who  tolerate  ACEIs  or  ARBs,  these  may  be  replaced  by
sacubitril/valsartan.  In  view  of  the  risk  of  bradyarrhythmia
in  this  condition,  it  is  important  to  monitor  the  patient’s
heart  rate,  since  beta-blockers  lower  heart  rate.50,67,90
Heart  transplantation  is  an  alternative  for  patients  with
Chagas  cardiomyopathy.  Survival  at  one  year  (71%)  and
10  years  (46%)  after  transplantation  is  better  than  in  patients
who  undergo  the  procedure  for  other  reasons.91 A  possible
complication  of  this  treatment  is  reactivation  of  the  dis-
ease  secondary  to  post-transplantation  immunosuppression;
this  should  be  treated  with  benznidazole.92 Some  stud-
ies  show  that  a  reduced  immunosuppressive  regimen  does
not  increase  allograft  rejection  in  patients  and  is  associ-
ated  with  lower  rates  of  reactivation  of  Chagas  disease.93,94
Recently,  the  first  heart  transplantation  in  a  patient  with
Chagas  cardiomyopathy  in  Portugal  was  performed.  After
one  year  of  follow-up,  the  patient  improved  from  NYHA
class  IV  to  class  I,  with  no  sign  of  rejection  or  disease
reactivation.95
Patients  with  symptomatic  sinus  node  dysfunction  or
advanced  AV  block  are  eligible  for  pacemaker  implantation.
Precise  indications  do  not  usually  differ  from  those  for  other
underlying  conditions.50 Left  bundle  branch  block  associated
with  heart  failure  can  be  treated  with  resynchronization
therapy.  For  this,  the  patient  should  preferably  present
LVEF  ≤35%,  QRS  >130  ms  and  sinus  rhythm.  However,  there
is  scarce  evidence  to  support  this  procedure  for  patients
with  Chagas  cardiomyopathy  and  right  bundle  branch
block.67
Ventricular  arrhythmias  are  an  important  risk  factor  for
sudden  death  in  patients  with  Chagas  cardiomyopathy.  How-
ever,  there  is  no  fixed  protocol  for  the  management  of
these  complications.  Patients  with  preserved  ventricular
function  have  no  indication  for  treatment.  Although  there
is  no  evidence  that  it  prevents  sudden  death,  patients  with
both  ventricular  arrhythmias  and  heart  failure  are  eligi-
ble  for  treatment  with  amiodarone  associated  with  drugs
for  ventricular  dysfunction  with  reduced  LVEF.  Amiodarone
improves  symptoms  and  reduces  the  density  of  ventricular
arrhythmias.67
An  implantable  cardioverter-defibrillator  (ICD)  is  indi-
cated  for  patients  with  arrhythmias  with  high  mortality  such
as  sustained  ventricular  tachycardia  or  ventricular  fibrilla-
tion,  or  who  have  had  an  episode  of  resuscitated  sudden
death.  The  use  of  this  device  led  to  a  72%  reduction  in
mortality  compared  to  amiodarone  alone.96 Patients  with
preserved  ventricular  function  may  be  more  difficult  to
identify,  making  ICD  indication  more  difficult.  After  ICD
placement,  amiodarone  plus  a  beta-blocker  should  be  con-
sidered  in  order  to  avoid  the  deleterious  effects  of  frequent
shocks.97 Patients  with  well-tolerated  sustained  ventric-
ular  tachycardia  and  preserved  ventricular  function  may
undergo  ablative  therapy  associated  with  amiodarone  to




Male gender  2
ECG: electrocardiogram; NYHA: New York Heart Association.
rognosis
he  prognosis  of  Chagas  disease  is  highly  variable,  as  the
ondition  can  affect  various  systems,  and  in  the  case  of  car-
iomyopathy  its  pathophysiology  is  complex,  leading  to  a
ide  range  of  disease  phenotypes.  The  main  cause  of  mor-
ality  in  the  chronic  phase  is  sudden  death,  accounting  for
5-65%  of  deaths.98
The  Rassi  score  (Table  2)  is  used  to  stratify  mortal-
ty  risk  in  patients  in  the  chronic  phase  and  with  cardiac
nvolvement.99 The  variables  assessed  in  the  score  are  gen-
er,  low  QRS  voltage  on  ECG,  nonsustained  ventricular
achycardia,  global  or  segmental  left  ventricular  wall  motion
bnormalities,  cardiomegaly  on  chest  X-ray  and  heart  failure
NYHA  class  III  or  IV).  The  score  estimates  10-year  mor-
ality  risk,  classifying  patients  as  high  risk  (12-20  points),
ntermediate  risk  (7-11  points)  or  low  risk  (0-6  points).  In
he  development  and  validation  cohorts  on  which  the  score
as  based,  the  10-year  mortality  rates  for  high,  intermedi-
te  and  low  risk  patients  were  84-85%,  37-44%  and  9-10%,
espectively.99 The  presence  of  nonsustained  ventricular
achycardia  is  associated  with  a  2.15-fold  increased  risk  of
ortality,  and  the  combination  of  this  arrhythmia  with  left
entricular  systolic  dysfunction  is  associated  with  a  15.1-fold
ncreased  risk  for  subsequent  death.100
onclusion
hagas  disease  is  a neglected  illness  that  has  crossed  the
orders  of  endemic  regions  and  reached  North  America,
urope,  Australia  and  Japan.  Nowadays,  oral  transmission
s  the  main  mechanism  for  perpetuating  the  disease.
The  systemic  involvement  of  the  disease  affects  various
rgans  including  the  esophagus,  colon,  heart  and  central
ervous  system.  Cardiac  changes  in  Chagas  disease  include
ilated  cardiomyopathy,  thromboembolic  phenomena,  and
rrhythmias  that  may  lead  to  sudden  death.  Thus,  investi-
ation  of  this  stage  of  the  disease  should  be  aimed  at  these
ossible  complications.
There  is  no  specific  treatment  for  Chagas  heart  dis-
ase.  Clinical  management  of  heart  failure  is  based  on
onventional  treatment  for  dilated  cardiomyopathy.  Heartrognosis  of  the  disease  is  variable  and  the  Rassi  score  is
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